Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN 1 20 versus MIRCETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN 1 20 versus MIRCETTE.
MICROGESTIN 1/20 vs MIRCETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
None Documented
None Documented
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Category C
Category C
Oral Contraceptive
Oral Contraceptive